Rimonabant

Rimonabant (also known as SR141716; trade names Acomplia, Bethin, Monaslim, Remonabent, Riobant, Slimona, Rimoslim, Zimulti, and Riomont) is an anorectic antiobesity drug that has been withdrawn from the market. It is an inverse agonist for the cannabinoid receptor CB1. Its main effect is reduction in appetite.

Rimonabant was the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it was indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m², or patients with a BMI greater than 27 kg/m² with associated risk factors, such as type 2 diabetes or dyslipidaemia. In the UK, it was available beginning in July 2006. As of 2008, the drug was available in 56 countries. On 23 October 2008, the European Medicines Agency (EMEA) issued a press release stating its Committee for Medical Products for Human Use (CHMP) had concluded the benefits of Acomplia no longer outweighed its risks, and subsequently recommended the product be suspended from the UK market. Sanofi-Aventis later released a press statement stating the drug had been suspended. Approval of the drug was officially withdrawn by the EMEA on 16 January 2009.

Read more about RimonabantHistory, Side Effects, Reaction

Other articles related to "rimonabant":

Cannabinoid Receptor Antagonist - Drug Design - Rimonabant
... Rimonabant, also known by the systematic name, is a 1,5-diarylpyrazole CB1 receptor antagonist (Figure 2) ... Rimonabant is not only a potent and highly selective ligand of the CB1 receptor, but it is also orally active and antagonizes most of the effects of cannabinoid agonists ... Rimonabant has shown clear clinical efficacy for the treatment of obesity ...
Rimonabant - Reaction
... Rimonabant can be synthesized as follows. ...
Cannabinoid Receptor Antagonist - Drug Design - Diarylpyrazole Derivatives
... SR141716 (rimonabant) analogs have recently been described by several groups, leading to a good understanding of the structure-activity relationship (S ... (surinabant), a second generation antagonist, has a longer duration of action than rimonabant and enhanced oral activity ... appeared to be more potent and selective than rimonabant ...
Cannabinoid Receptor Antagonist - Drug Design - Other Derivatives
... more selective for CB1 compared with CB2 and displays in vivo activity similar to rimonabant ... Another approach used to develop analogs of rimonabant was to replace central pyrazole ring by another heterocycle ... The structure of this compound demonstrates the possibility that the amide moiety of rimonabant could be split into a lipophilic (benzyloxy) and a polar (nitrile ...
Cannabinoid Receptor Antagonist - Drug Design - Pharmacophore
... so far are close analogs or isosteres of rimonabant ... pyrazole in rimonabant) substituted by two aromatic moieties, A and B ... In Figure 4 rimonabant is used as an example ...